ABBV vs TMO
ABBV: A diversified global biopharmaceutical leader with a strong footprint in immunology, neuroscience, and aesthetics, supported by a pipeline expanding into obesity. TMO: A massive, diversified life sciences conglomerate providing the essential infrastructure, tools, and services that enable scientific research and global healthcare diagnostics.
Side-by-side fundamentals
| Metric | ABBV | TMO | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $272.42 | $651.98 | |
| Market cap | $481.4B | $241.1B | |
| P/E as of 2026-10-08 | 76.54 | 35.10 | TMO lower |
| PEG as of 2026-10-08, 3-year EPS CAGR to FY2025 | n/a | 169.13 | |
| Net margin FY2025, SEC XBRL | +6.9% | +15.0% | TMO higher |
| Operating margin FY2025, SEC XBRL | +24.6% | +17.4% | ABBV higher |
| ROE FY2025, SEC XBRL | n/a | +12.6% | |
| ROA FY2025, SEC XBRL | +3.2% | +6.1% | TMO higher |
| Debt / equity as of 2026-09-03 | 49.22 | 0.81 | TMO lower |
| Revenue growth (YoY) as of 2026-09-03 | +10.4% | +7.2% | ABBV higher |
| Revenue CAGR (3y) SEC XBRL | +1.8% | -0.3% | ABBV higher |
| Dividend yield as of 2026-09-03 | +2.6% | +0.3% | ABBV higher |
| Dividend streak (yrs) SEC XBRL | 9 | 14 | TMO higher |
| Beta as of 2026-09-03 | 0.27 | 0.77 | |
| 1-year return as of 2026-10-08 close | +17.8% | +21.6% | TMO higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.